Open original FDA record ↗Recall record
- FDA identifier
- Z-1461-2020
- Company in FDA record
- Response Biomedical Corp.
- FDA record creation date
- Mar 10, 2020
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
The form received three complaints related to the user obtaining a result that fell below the target range for CK-MB provided in the RAMP Cardiac Controls Instructions for Use. Via in-house monitoring, determined that liquid Cardiac Control has seen a decrease in CK-MB Levels of up to 57% signal loss within 11 months. Shelf-life of product is 24 months.
Source facts
- Action
- On 03/15/2019, the firm sent an "Field CORRECTION" Letter via email informing them that the specific lot (4244CK) has seen a decrease in CK-MB levels of up to 57% signal loss within 11 months of the Randox-stated shelf life of 24 months. Customers are instructed to: -Inspect their stock levels and report level of unused inventory; -Notify the Recalling Firm's Technical Support using Field Correction Response Form indicating the replacement quantity; -Confirm lot-specific ranges per website (www.responsebio.com/cardiaccountrols) -Substitute affected Lot # 070318 with replacement stock as appropriate. For any further questions or information contact Technical Support at techsupport@responsebio.com.
- Initiated
- 2019-03-15
- Root cause
- Device Design
- Terminated
- 2022-06-09
- Distribution
- Worldwide distribution: US Nationwide distributions in the states of IN, GA, OK, KS, AZ, SC, NE, NC, MI, FL, CA, MN, and AR. Countries of Canada, Italy, Malaysia, Kuwait, Saudi Arabia, UAE, Ukraine, Russia, Dominican Republic, France, Mexico, Colombia, Singapore, China, Serbia, Romania, and Philippine.
- Recall number
- Z-1461-2020
- Recall status
- Terminated
- CDRH record ID
- 178445
- FDA record created
- 2020-03-10
- Recall event number
- 84514